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Purpose: To determine whether there is a difference in neuroretinal function and in macular 
pigment optical density between persons with high- and low-risk gene variants for age-related 
macular degeneration (AMD) and no ophthalmoscopic signs of AMD, and to compare the 
results on neuroretinal function to patients with manifest early AMD. 
 
Methods and Participants: Neuroretinal function was assessed with the multifocal 
electroretinogram (mfERG) for 32 participants (22 healthy persons with no AMD and 10 
early AMD patients). The 22 healthy participants with no AMD had high- or low-risk 
genotypes for either CFH (rs380390) and/or ARMS2 (rs10490924). Trough-to-peak response 
densities and peak-implicit times were analyzed in 5 concentric rings. Macular pigment 
optical densitometry was assessed by customized heterochromatic flicker photometry. 
 
Results: Trough-to-peak response densities for concentric rings 1 to 3 were, on average, 
significantly greater in participants with high-risk genotypes than in participants with low-
risk genotypes and in persons with early AMD after correction for age and smoking (p<0.05). 
The group peak- implicit times for ring 1 were, on average, delayed in the patients with early 
AMD compared with the participants with high- or low-risk genotypes, although these 
differences were not significant. There was no significant correlation between genotypes and 
macular pigment optical density. 
 
Conclusion: Increased neuroretinal activity in persons who carry high-risk AMD genotypes 
may be due to genetically determined subclinical inflammatory and/or histological changes in 
the retina. Neuroretinal function in healthy persons genetically susceptible to AMD may be a 
useful additional early biomarker (in combination with genetics) before there is clinical 
manifestation. 
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Psychophysical and electrophysiological measures of central retinal function have been 
repeatedly shown to be reduced in patients with manifest early age-related macular 
degeneration (AMD).[1-13] Psychophysical tests of dark adaptation,[14] glare recovery[2, 
15] and flicker sensitivity[16, 17] were identified as markers of visual function deficits before 
loss of visual acuity. The introduction of multifocal electroretinography (mfERG) ,[18]  
enabled a detailed determination of local neuroretinal function in cone and rod-mediated 
pathways in AMD.[6, 7, 13, 17, 19-22] These findings have been replicated in recent 
studies.[23] Reasons for conflicting results regarding neuroretinal function deficits in early 
AMD have been discussed and these include different paradigms, analysis methods and 
phenotypes,[5, 23-25] however, the effect of genotype on neuroretinal function has not been 
studied.  
 
Both the rod and cone-mediated visual pathways can be affected in early stages of AMD, 
with evidence of greater rod than cone vulnerability.[6, 26] The current understanding is that 
the pathomechanisms of AMD involve genetic and environmental risk factors.[24, 27] While 
the genetics cannot fully explain AMD,[28] gene variants account for more than 50% of the 
risk. This has led to the use of statistical models that have included high-risk genotypes and 
environmental risk factors with the aim to better predict AMD.[29-33] These models may be 
extended by including visual function tests as biomarkers for vision loss before there are 
clinical signs of AMD. [28, 34]  
 
We have shown in our previous investigations that persons with no signs of AMD but who 
are genetically at high-risk, have on average, worse combined rod and cone function 
(mesopic vision) than those with low-risk gene variants.[34] Our results indicated that there 
was normal cone-function when rod activity was silenced but the combined rod and cone 
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function was reduced in high–risk genotypes. In this study we investigate a subset of this 
group to determine the effect of genotypes on neuroretinal function. We compared 
neuroretinal function between healthy persons with high and low-risk genotypes but no 
clinical signs of AMD  and early AMD patients, with the aim to provide a genotype- 
phenotype neuroretinal function signature that may reflect the electrophysiological dynamics 
in subclinical and manifest early AMD. Given lower macular pigment optical density 
(MPOD) has been associated with AMD risk genotypes in a small group (n=4) of patients 
homozygous for the CFH and ARMS2,[35] we were also interested in the relationship 
between  MPOD and genotypes in our cohort of healthy participants. 
 
Participants and Methods 
We investigated the right eye of 22 healthy persons (mean age 56.1 yrs ± 4.8 SD) who have 
been previously genotyped for the common AMD CFH (rs380390) and ARMS2 (rs10490924) 
risk gene variants using optimized gene-expression assays (TaqMan Gene Expression Assay; 
Applied Biosystems, Inc., Foster City, CA).[34] Of these, 14 participants were either 
homozygous or heterozygous for one or both of the high-risk genotypes and 8 participants did 
not carry any of the determined high-risk genes (Table 1). The odds ratios and thus risks were 
assigned to each genotype according to published data:[36, 37] CFH (rs380390), CC OR = 
7.4, GG + CG OR = 1; ARMS2 (rs10490924), TT OR = 6.09, GT OR = 1.35, GG OR = 1.   
The investigator was masked to the genotyping results. All healthy participants had visual 
acuity better than 6/6 and no refractive errors more than ± 3 diopters.[38] The participants 
had no ophthalmoscopic signs of AMD and all had normal central retinal thickness measured 
with optical coherence tomography (OCT) (Stratus III, Carl Zeiss Pty Ldt, Oberkochen, 
Germany) as determined by an ophthalmologist (BF).  
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For comparison with the healthy participants without clinical signs of AMD, we included ten 
participants (mean age 73.1 yrs ±2.7SD) with manifest early AMD (grading according to 
AREDS)[39] who had been previously tested in our laboratory[22] and who had not been 
genotyped (Table 2). Fundus grading was based on colour fundus photographs (Zeiss Jena 
Mydriatic Fundus Camera) of the central 30º and retinal changes were graded independently 
by two experienced observers who were masked to the results. All early AMD patients had 
visual acuity of 6/15 or better, drusen > 63μm and/or retinal pigment abnormalities but no 
late geographic or neovascular AMD.  
 
Written informed consent was obtained from all participants and the study was approved by 
the Human Research Ethics Committee of the Queensland University of Technology and 
which followed the tenets of the Declaration of Helsinki. 
 
Multifocal electroretinogram  
We performed neuroretinal function testing with the multifocal electroretinogram (mfERG) 
(VERIS, EDI, Redwood City, CA). The stimulus array of the mfERG was presented on a 
calibrated 9 inch CRT monitor (screen refresh rate 13.3 ms, frame rate 75 Hz); the display 
consisted of 103 hexagons (ranging in size from about 3.2 to 5 deg in horizontal extent) and 
subtended approximately 25 degrees (Figure 1A). The binary m-sequence was 213-1 frames 
long. A slow flash mfERG (sf-mfERG) paradigm was used for better detection of subclinical 
changes in adaptation compared to the conventional fast-flicker mfERG.[40, 41] The positive 
(N1P1) waveform component of both paradigms, the fast flicker (ff)mfERG[42] and sf-
mfERG[43] however, contains mainly contributions from ON and OFF bipolar cells.   
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The stimulus sequence was slowed by inserting 3 blank frames after the initial m-sequence 
frame where the hexagons had a 50% probability of being white (200 cd/m2) or black (3 
cd/m2), and the next 3 frames remained dark (3 cd/m2) resulting in a time-average luminance 
of 26 cd/m2. The surround luminance was always 52 cd/m2. Recordings followed the ISCEV 
standard[44] and were made monocularly and in ambient room lighting conditions. 
Recordings were divided into sixteen segments resulting in a total recording time of ~8 
minutes. We used DTL electrodes as active electrodes. The participant’s right pupil was 
dilated with 0.5% tropicamide; a pupil diameter greater than 8 mm was achieved in all 
participants. Refractive errors were corrected using the VERIS eye refractor/camera unit so 
that optimal acuity could be achieved. During recording, the VERIS system displayed a video 
image of the eye and the ERG signal. Contaminated segments due to fixation loss or repeated 
blinks were discarded and re-recorded. Retinal signals were band-pass filtered between 10 
and 300 Hz, amplified 100,000 x and sampled every 0.83 ms. A single spatial averaging was 
performed as per ISCEV/VERIS recommendations.[44] We determined the trough N1 to 
peak P1 response density (RD), N1P1-RD and peak P1 implicit time (time from onset of 
stimulus to first peak), P1-IT after averaging the 103 hexagons into 5 concentric rings (ring 1: 
0º -5º, ring 2: 5º -9º, ring 3: 9º -13.5º, ring 4: 13.5º -19º, ring 5: 19º -25º) (Figure 1A).[22] 
The concentric ring averaging was based on the predilection of first histological and 
functional changes in AMD being centrally and paracentrally.[26, 45] 
 
Macular pigment optical density  
Macular pigment optical density (MOPD) was estimated with the Macular Pigment 
Densitometer (Macular Metrics II, LLC, Providence, USA) in 20 out of 22 healthy 
participants (two participants were unavailable to return for MPOD measurements). In brief, 
the system is based on Heterochromatic Flicker Photometry (HPF).[46] A 0.5º spot is 
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presented in the fovea and a 2º spot is presented 7º paracentrally. The stimulus is a flickering 
light that alternates between 460 nm which is absorbed by macular pigment and 520 nm 
which is not absorbed by macular pigment. The participant’s task is to adjust the stimulus 
radiance to minimize or eliminate any flicker in the stimulus. The amount of 460 nm light 
required to achieve minimum flicker is used to calculate the MPOD. The Macular Pigment 
Densitometer allows individual adjustment of the flicker frequency: at the start of a practise 
run, the flicker frequency is determined where the participant finds a zone of no flicker by 
increasing or decreasing the flicker frequency. All participants performed four measurements 
at both  central and peripheral locations. The MPOD was derived by subtracting the log 
foveal sensitivity from the log peripheral (7º) sensitivity using the manufacturer’s software. 
MPOD was normal in all healthy participants (mean 0.52 ± 0.2SD).  
 
Statistical analyses 
We used PASW Statistics 18 (SPSS Inc Chicago, IL) for analysis. All data were normally 
distributed and therefore parametric analyses were performed. The mfERG N1P1-response 
density and P1-implicit time data were analysed using mixed design repeated measures 
analysis of variance to determine effects between the three groups (high-risk AMD genotype, 
low-risk AMD genotype and early AMD groups). Post-hoc analysis was performed when 
significant effects were found. Age and smoking status were included as confounding 
variables and entered as covariates in the statistical analysis. Pearson’s correlation was used 
to determine a relationship between the MPOD and haplotype combinations. A p-value of 
0.05 or less was considered statistically significant. 
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Results 
The slow flash (sf)-mfERG results of four participants were excluded from analysis due to 
poor fixation.[44] The mfERG results of the remaining 18 participants (11 with high-risk and 
7 with low-risk genotypes) for N1P1-RD and P1-IT are shown in Table 1.  The sf-mfERG 
results for the ten early AMD patients are outlined in Table 2. Figure 1B-D shows three 
representative mfERG trace arrays: a healthy funduscopically normal participant with a high-
risk genotype (B), a healthy funduscopically normal person with a low-risk genotype (C) and 
a patient with early AMD (D). The person who is genetically at high-risk (B) demonstrates 
larger (supernormal) N1P1 response amplitudes compared to the healthy person with the low-
risk genotype (C). The early AMD patient (D) shows lower responses and has delayed central 
responses compared to the high-risk (B) and low-risk genotype (C). The mean mfERG data 
(N1P1-RD and P1-IT) of the three groups are demonstrated in Figure 2 (upper and lower 
panels) and show the same response patterns as the individual observers. The MPOD results 
for each of the 19 healthy participants are shown in Table 3 (two participants could not 
perform the MPOD and were excluded from the 21 enrolled healthy persons) and these where 
within the normal range reported in the literature.[47] 
 
Statistical analysis was performed and a significant difference was detected between the three 
groups for the N1P1-RD (F2, 25 = 5.1, p=0.01) demonstrating that healthy persons with high-
risk genotypes had on average significantly larger N1P1-RD for rings 1-3 compared to the 
participants with low-risk genotype (post-hoc p<0.01) and early AMD patients (post-hoc 
p<0.05). After correction for age, the difference between the three groups was still significant 
(F2, 25 = 3.6, p=0.04). In the cohort of (healthy and early AMD) participants there were no 
current smokers. However, after including past smokers as a covariate in the statistical model, 
there was a significant difference between the three groups (F2,24 = 4.1, p=0.03). 
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There was no significant difference between any of the groups for the P1-IT for each ring (F2, 
25 = 0.6, p=0.5) but the AMD group demonstrated on average delayed implicit times for ring 
1 group compared to the other two groups (Figure 2, Table 1). There was no significant 
correlation between the genotype and macular pigment optical density  (r = 0.14, p = 0.5). 
 
Discussion 
Our study identified significantly greater central neuroretinal function in healthy participants 
with high-risk genotypes compared to those with low-risk genotypes with no clinical signs of 
AMD (as determined ophthalmoscopically according to AREDS classification and with the 
Stratus OCT). These findings and our previous research[34] in healthy observers have 
important implications for studies on “normal ageing” as they provide a way to differentiate 
neuroretinal and psychophysical function between healthy older persons. Based on our 
findings we infer that there are clinically “normal” subgroups whose function may be 
differentiated on the basis of their genetics. Healthy high risk genotypes however, were not 
significantly associated with lower MPOD levels suggesting further investigations into a 
larger sample of homozygous AMD risk genotypes are required.[35] 
 
Supernormal responses in electrophysiology are rare, but not novel observations. They are 
thought to be of genetic, ischemic, inflammatory or toxic origin and can be found in patients 
with cone dystrophy,[48] retinal vein occlusion,[49] uveitis [50-52] and in siderosis bulbi 
[53] and can affect the cone [49] and rod-mediated pathways.[54] In particular, supernormal 
responses have been described as the earliest detectable signs in inflammatory disease before 
disease is ophthalmoscopically manifest.[50-52] Once inflammatory disease is manifest, the 
neuroretinal responses decrease to normal and subnormal values.[50] One of the main risk 
factors of AMD is age,[55] and ageing itself has been linked with chronic inflammation.[56] 
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Moreover, the pathomechanisms in AMD involve a dysregulated inflammatory/immune 
response due to gene variants in the complement factor H (CFH) region.[57] It is thought that 
uncontrolled inflammation occurs because of this gene variant. Drusen, the hallmark and first 
clinical signs of AMD are considered as by products of this local, chronic inflammation.[58] 
Our findings of supernormal neuroretinal responses in people with high-risk genotypes 
related to the gene variants in the CFH region, may therefore reflect a genetically determined 
subclinical and low grade inflammation before drusen are ophthalmoscopically evident. 
However, drusen may be apparent on high definition (HD) OCT but not on 
ophthalmoscopy/fundus photography[59] and Stratus OCT, therefore beginning pathology 
cannot be completely excluded in our healthy cohort of participants. It would be interesting to 
determine if healthy participants with high risk genotypes and supernormal ERGs show 
corresponding changes with the HD-OCT. 
 
We link our results with previous findings in our laboratory where we demonstrated reduced 
mesopic vision in persons genetically at-risk for AMD.[34] Under mesopic conditions both 
cone and rod pathways are active.[60] Although the stimulus mean luminance conditions 
with the slow-flash mfERG were low photopic,[61] rod-driven ERG responses can be 
obtained at photopic illuminances and with stimuli containing low temporal frequencies[62] 
as with the mfERG recording used in this study. Normal rod function is crucial for cone 
survival and a protective role of rods over cones has been suggested.[63] Cone function may 
be altered when operating in the presence of defective rods which results in supernormal 
photopic mfERG responses. Our working hypothesis is that increased neuroretinal function in 
persons genetically at-risk for AMD would occur because their retina is genetically 
determined to age faster and because they are susceptible to chronic inflammation. An early 
histological correlate of this process (and before there are clinically detectable drusen) may 
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be the expansion of cone photoreceptor inner segments to fill the spaces where there is rod 
loss as found in early AMD as well as in normal ageing.[64, 65] The larger photoreceptor 
inner segment contain a higher number of mitochondria[66] which may give them greater 
capacity for enhanced output.  
 
We propose a hypothetical model that links neuroretinal function with subclinical and clinical 
changes that occur in AMD. Figure 3 demonstrates individual N1P1 response densities for 
the five rings of one representative for each of the healthy high-risk genotype group and the 
low-risk genotype group, and two representatives of the early AMD group (one with less 
progressed early AMD and drusen size less than 125 μm, and one early AMD patient with 
more progressed funduscopic changes and with drusen size greater than 125 μm). The 
individuals in this example are not significantly different from the mean group data (Figure 
2). In stage 1 (subclinical stage, normal ophthalmoscopy and Stratus OCT but histological 
signs of cell loss) healthy persons genetically at-risk for AMD have supernormal neuroretinal 
responses in the central, para- and pericentral retinal areas (rings 1-3). In stage 2 (clinical, 
early AMD drusen <125 μm) where first funduscopic signs become apparent, a pronounced 
decrease of neuroretinal function in particular in paracentral and pericentral areas (rings 2-3) 
is evident where changes in retinal topography occur first in AMD.[67]  In that sense, 
neuroretinal responses may decrease once the first clinical signs of inflammation[68, 69] 
occur (e.g small drusen). In stage 3 (AMD drusen ≥ 125 μm), a further decrease for central, 
para- and pericentral regions (rings 1-3) below normal values occurs as the disease progresses 
to more advanced forms of AMD. This model is in accordance with electrophysiological and 
histopathological findings in experimental inflammatory disease where a decrease in 
neuroretinal responses coincides with histological changes.[51] The subnormality of the ERG 
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correlates with the photoreceptor and bipolar loss in ageing[70, 71] and with drusen in early 
AMD.[72] 
 
A potential confounding factor of this model is that the genotypes of the early AMD group 
were not known and there is a ~40% risk of having AMD without these high-risk gene 
variants.[73]  Some of the early AMD patients may have had other genes or/and 
environmental risk factors involved and different electrophysiological features may apply. 
The conflicting findings from mfERG studies that report either normal or decreased 
responses in early AMD[5, 74] could therefore be explained by patients having different 
genotypes in addition to technical/analysis differences.  Nevertheless, patients with manifest 
disease can be considered to undergo the pathological processes which are encapsulated by 
the final stage of this model, irrespective of their individual gene-environment exposure.  
 
In summary, we have identified supernormal neuroretinal responses in healthy persons with 
high-risk AMD genotypes without clinical signs of the disease. Given our findings may 
appear counter-intuitive to results that might be expected if high-risk genotypes were 
hypothesized to decrease neuroretinal activity, we consider our results as interesting 
preliminary data that should be further investigated in larger longitudinal studies.  In support 
of our findings is a recent animal study suggesting that retinal function is genetically 
determined but that there are numerous phenotypic variances in retinal function even in the 
healthy retina.[75]   The electrophysiological findings of supernormality may be linked with 
genetically determined inflammatory and subclinical ageing processes at the histological 
level that are established factors in the pathomechanisms of AMD. The multifocal 
electroretinogram is now being established as a robust technology with low variability in 
healthy participants.[76] In disease, neuroretinal deficits can be detected in retinal locations 
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before there is clinical evidence of disease as has been shown in diabetic retinopathy,[77] in 
early AMD[20] and  due to discrete changes in oxygenation[78] that may occur via choroidal 
blood flow disturbances in AMD.[79]  It is further recognized as a valuable tool for 
documenting treatment effects in AMD.[80, 81] Our findings suggest that neuroretinal 
function may have a value as a biomarker in addition to genetic prediction models for the 
detection of people at-risk of AMD before there is funduscopic evidence of AMD.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Feigl B, Morris CP, Brown B, Zele AJ. Archives of Ophthalmology 2012;130(11):1402-1409. 
 
14 
 
 
 
 
 
References 
1. Brown, B., et al., Cone adaptation in age-related maculopathy. Am J Optom Physiol Opt, 
1986. 63: p. 450-454. 
2. Collins, M. and B. Brown, Glare recovery and its relation to other clinical findings in age 
related maculopathy. Clin Vis Sci, 1989. 4: p. 155-163. 
3. Haegerstrom-Portnoy, G. and B. Brown, Two-color increment thresholds in early age-related 
maculopathy. Clin Vis Sci, 1989. 4: p. 165-172. 
4. Phipps, J.A., et al., Flicker perimetry losses in age-related macular degeneration. Invest 
Ophthalmol Vis Sci, 2004. 45: p. 3355-3360. 
5. Feigl, B., et al., Cone-mediated multifocal electroretinogram in early age-related 
maculopathy and its relationships with subjective macular function tests. Curr Eye Res, 2004. 
29: p. 327-336. 
6. Feigl, B., et al., Cone- and rod-mediated mfERG in early age-related maculopathy. Eye, 2005. 
19: p. 431-441. 
7. Feigl, B., et al., Adaptation responses in early age-related maculopathy. Invest Ophthalmol 
Vis Sci, 2005. 46: p. 4722-4727. 
8. Mayer, M.J., et al., Mid-frequency loss of foveal flicker sensitivity in early stages of age-
related maculopathy. Invest Ophthalmol Vis Sci, 1992. 33: p. 3136-3142. 
9. Owsley, C., et al., Delays in rod-mediated dark-adaptation in early age-related maculopathy. 
Ophthalmology, 2001. 108: p. 1196-1202. 
10. Jackson, G.R., C. Owsley, and C.A. Curcio, Photoreceptor degeneration and dysfunction in 
aging and age-related maculopathy. Ageing Research Reviews, 2002. 1(3): p. 381-396. 
11. Zele, A.J., et al., Disclosing disease mechanisms with a spatio-temporal summation 
paradigm. Graefe's Arch Clin Exp Ophthalmol, 2006. 244: p. 425-432. 
12. Dimitrov, P.N., et al., Measuring rod and cone dynamics in age-related maculopathy. Invest 
Ophthalmol Vis Sci, 2008. 49: p. 55-65. 
13. Feigl, B., et al., The rod-mediated multifocal electroretinogram in aging and in early age-
related maculopathy eyes. Curr Eye Res, 2006. 31: p. 635-644. 
14. Brown, B., et al., Dark adaptation in age-related maculopathy. Ophthal Physiol Opt, 1986. 6: 
p. 81-84. 
15. Collins, M. and B. Brown, Glare recovery and age-related maculopathy. Clin Vis Sci, 1989. 4: 
p. 145-153. 
16. Mayer, M.J., et al., Foveal flicker sensitivity discriminates ARM risk from healthy eyes. Invest 
Ophthalmol Vis Sci, 1992. 33: p. 3143-3149. 
17. Falsini, B., et al., Retinal sensitivity to flicker modulation: reduced by early age-related 
maculopathy. Invest Ophthalmol Vis Sci, 2003. 41: p. 1498-1506. 
18. Sutter, E.E. and D. Tran, The field topography of ERG components in man-I. the photopic 
luminance response. Vision Res, 1992. 32: p. 433-446. 
19. Tzekov, R.T., C. Gerth, and J.S. Werner, Senescence of human multifocal electroretinogram 
components: a localized approach. Graefe's Arch Clin Exp Ophthalmol, 2004. 242: p. 549-
560. 
20. Gerth, C., et al., Cone-mediated multifocal electroretinogram in age-related macular 
degeneration. Arch Ophthalmol, 2006. 124: p. 345-352. 
Feigl B, Morris CP, Brown B, Zele AJ. Archives of Ophthalmology 2012;130(11):1402-1409. 
 
15 
 
21. Feigl, B., J. Lovie-Kitchin, and B. Brown, Objective functional assessment of age-related 
maculopathy: a special application for the multifocal electroretinogram. Clin Exp Optom, 
2005. 88: p. 304-312. 
22. Feigl, B., et al., Postreceptoral adaptation abnormalities in early age-related maculopathy. 
Vis Neurosci, 2006. 23: p. 863-870. 
23. Gin, T.J., C.D. Luu, and R.H. Guymer, Central retinal function as measured by the multifocal 
electroretinogram and flicker perimetry in early age-related macular degeneration. Invest 
Ophthalmol Vis Sci, 2011: p. Epub ahead of print. 
24. Feigl, B., Age-related maculopathy: Linking aetiology and pathophysiological changes to the 
ischaemia hypothesis. Prog Ret Eye Res, 2009. 28: p. 63-86. 
25. Hogg, C.R. and U. Chakravarthy, Visual function and dysfunction in early and late age-related 
maculopathy. Prog Ret Eye Res, 2006. 25: p. 249-276. 
26. Curcio, C.A., N.E. Medeiros, and L.J. Millican, Photoreceptor loss in age-related macular 
degeneration. Invest Ophthalmol Vis Sci, 1996. 37: p. 1236-1249. 
27. Bird, A.C., Age-related macular disease: an ongoing challenge. Clin Exp Ophthalmol, 2003. 
31: p. 461-463. 
28. Feigl, B. and C.P. Morris, The challenge of predicting macular degeneration. Curr Med Res 
Opin, 2011. 27(9): p. 1745-8. 
29. Seddon, J., M., et al., Association of CFH Y402H and LOC387715 A69S with progression of 
age-related macular degeneration. JAMA, 2007. 297: p. 1793-1800. 
30. Seddon, J.M., et al., Prediction model for prevalence and incidence of advanced age-related 
macular degeneration based on genetic, demographic, and environmental variables. Invest 
Ophthalmol Vis Sci, 2009. 50(5): p. 2044-53. 
31. Seddon, J.M., et al., Risk Models for Progression to Advanced Age-Related Macular 
Degeneration Using Demographic, Environmental, Genetic, and Ocular Factors. 
Ophthalmology, 2011. 
32. Maller, J., et al., Common variation in three genes, including a noncoding variant in CFH, 
strongly influences risk of age-related macular degeneration. Nat Genet, 2006. 38(9): p. 
1055-9. 
33. Williamson, J.F., et al., Almost total protection from age-related macular degeneration by 
haplotypes of the Regulators of Complement Activation. Genomics, 2011. 
34. Feigl, B., et al., Persons with age-related maculopathy risk genotypes and clinically normal 
eyes have reduced mesopic vision. Invest Ophthalmol Vis Sci, 2011. 52(2): p. 1145-50. 
35. Loane, E., et al., The association between macular pigment optical density and CFH, ARMS2, 
C2/BF, and C3 genotype. Exp Eye Res, 2011. 
36. Klein, R.J., et al., Complement factor H polymorphism in age-related macular degeneration. 
Science, 2005. 308(5720): p. 385-9. 
37. Yang, Z., et al., A variant of the HTRA1 gene increases susceptibility to age-related macular 
degeneration. Science, 2006. 314: p. 992-993. 
38. Palmowski, A., et al., The effect of refractive blur on the multifocal electroretinogram, in Doc 
Ophthalmol1999. p. 41-54. 
39. Age-Related Eye Disease Study Research Group, The age-related eye disease study system 
for classifying age-related macular degeneration from stereoscopic color fundus 
photographs: the Age-Related Eye Disease Study Report Number 6. Am J Ophthalmol, 2001. 
132: p. 668-681. 
40. Bearse, M.A.J., et al., Retinal function in normal and diabetic eyes mapped with slow flash 
multifocal electroretinogram. Invest Ophthalmol Vis Sci, 2004. 45: p. 296-304. 
41. Sutter, E.E., et al., Mapping inner retinal function through enhancement of adaptative 
components in the M-ERG. In Vision Science and its Application. OSA Tech Dig Ser, Optical 
Society of America, Washington, DC, 1999: p. 52-55. 
Feigl B, Morris CP, Brown B, Zele AJ. Archives of Ophthalmology 2012;130(11):1402-1409. 
 
16 
 
42. Hood, D.C., et al., Retinal origins of the primate multifocal ERG. Implication for the human 
response. Invest Ophthalmol Vis Sci, 2002. 43: p. 1673-1685. 
43. Rangaswamy, N.V., D.C. Hood, and L.J. Frishman, Regional variations in local contributions to 
the primate photopic flash ERG: revealed using the slow-sequence mfERG. Invest Ophthalmol 
Vis Sci, 2003. 44: p. 3233-3247. 
44. Hood, D.C., et al., ISCEV standard for clinical multifocal electroretinography (mfERG) (2011 
edition). Doc Ophthalmol, 2011. 
45. Swann, P.G. and J.E. Lovie-Kitchin, Age-related maculopathy. II: the nature of the central 
visual field loss. Ophthal Physiol Opt, 1991. 11: p. 59-70. 
46. Wooten, B.R., et al., A practical method for measuring macular pigment optical density. 
Invest Ophthalmol Vis Sci, 1999. 40(11): p. 2481-9. 
47. Raman, R., et al., Macular pigment optical density in a South Indian population. Invest 
Ophthalmol Vis Sci, 2011. 52(11): p. 7910-6. 
48. Foerster, M.H., U. Kellner, and A. Wessing, Cone dystrophy and supernormal dark-adapted b-
waves in the electroretinogram. Graefes Arch Clin Exp Ophthalmol, 1990. 228(2): p. 116-9. 
49. Gouras, P. and C.J. MacKay, Supernormal cone electroretinograms in central retinal vein 
occlusion. Invest Ophthalmol Vis Sci, 1992. 33(3): p. 508-15. 
50. Feigl, B., A. Haas, and Y. El-Shabrawi, Multifocal ERG in multiple evanescent white dot 
syndrome. Graefe's Arch Clin Exp Ophthalmol, 2002. 240: p. 615-621. 
51. Stanford, M.R. and J. Robbins, Experimental posterior uveitis. II. Electroretinographic studies. 
Br J Ophthalmol, 1988. 72(2): p. 88-96. 
52. Ikeda, H., et al., Electroretinography and electro-oculography to localize abnormalities in 
early-stage inflammatory eye disease. Doc Ophthalmol, 1989. 73(4): p. 387-94. 
53. Knave, B., The ERG and ophthalmological changes in experimental metallosis in the rabbit. 1. 
Effes of iron particles. Acta Ophthalmol (Copenh), 1970. 48(1): p. 136-58. 
54. Gouras, P., H.M. Eggers, and C.J. MacKay, Cone dystrophy, nyctalopia, and supernormal rod 
responses. A new retinal degeneration. Arch Ophthalmol, 1983. 101(5): p. 718-24. 
55. Smith, D., et al., Risk factors for age-related macular degeneration: Pooled findings from 
three continents. Ophthalmology, 2001. 108: p. 697-701. 
56. Medzhitov, R., Origin and physiological roles of inflammation. Nature, 2008. 454(7203): p. 
428-35. 
57. Donoso, L.A., et al., The role of inflammation in the pathogenesis of age-related macular 
degeneration. Surv Ophthalmol, 2006. 51: p. 137-152. 
58. Anderson, D.H., et al., The pivotal role of the complement system in aging and age-related 
macular degeneration: hypothesis re-visited. Prog Retin Eye Res, 2010. 29(2): p. 95-112. 
59. Jain, N., et al., Quantitative comparison of drusen segmented on SD-OCT versus drusen 
delineated on color fundus photographs. Invest Ophthalmol Vis Sci, 2010. 51(10): p. 4875-83. 
60. Zele, A.J., D. Cao, and J. Pokorny, Rod-cone interactions and the temporal impulse response 
of the cone pathway. Vision Res, 2008. 48(26): p. 2593-8. 
61. Hood, D.C., Assessing retinal function with the multifocal technique. Prog Ret Eye Res, 2000. 
19: p. 607-646. 
62. Kremers, J., D. Czop, and B. Link, Rod and S-cone driven ERG signals at high retinal 
illuminances. Doc Ophthalmol, 2009. 118(3): p. 205-16. 
63. Mohand-Said, S., et al., Normal rod photoreceptors increase cone survival in the retinal 
degeneration (rd) mouse. Proc Natl Acad Sci USA, 1998. 95: p. 8357-8362. 
64. Curcio, C.A., et al., Aging of the human photoreceptor mosaic: evidence for selective 
vulnerability of rods in central retina. Invest Ophthalmol Vis Sci, 1993. 34: p. 3278-3296. 
65. Curcio, C.A., Photoreceptor topography in aging and age-related maculopathy. Eye, 2001. 
15: p. 376-383. 
66. Hoang, Q.V., et al., Photoreceptor inner segments in monkey and human retina: 
mitochondrial density, optics, and regional variation. Vis Neurosci, 2002. 19(4): p. 395-407. 
Feigl B, Morris CP, Brown B, Zele AJ. Archives of Ophthalmology 2012;130(11):1402-1409. 
 
17 
 
67. Curcio, C.A., C. Owsley, and G.R. Jackson, Spare the rods, save the cones in aging and age-
related maculopathy. Invest Ophthalmol Vis Sci, 2000. 41: p. 2015-2018. 
68. Anderson, D.H., et al., A role for local inflammation in the formation of drusen in the aging 
eye. Am J Ophthalmol, 2002. 134: p. 411-431. 
69. Hageman, G.S. and R.F. Mullins, Molecular composition of drusen as related to substructural 
phenotype. Mol Vis, 1999. 5: p. 28-. 
70. Charng, J., et al., Age-related retinal function changes in albino and pigmented rats. Invest 
Ophthalmol Vis Sci, 2011. 52(12): p. 8891-9. 
71. Gao, H. and J.G. Hollyfield, Aging of the human retina. Invest Ophthalmol Vis Sci, 1992. 33: p. 
1-17. 
72. Gerth, C., et al., Assessment of multifocal electroretinogram abnormalities and their relation 
to morphologic characteristics with large drusen. Arch Ophthalmol, 2003. 121: p. 1404-1414. 
73. Schaumberg, D.A., et al., A prospective study of 2 major age-related macular degeneration 
susceptibility alleles and interactions with modifiable risk factors. Arch Ophthalmol, 2007. 
125(1): p. 55-62. 
74. Gin, T.J., C.D. Luu, and R.H. Guymer, Central retinal function as measured by the multifocal 
electroretinogram and flicker perimetry in early age-related macular degeneration. Invest 
Ophthalmol Vis Sci, 2011. 
75. Jelcick, A.S., et al., Genetic variations strongly influence phenotypic outcome in the mouse 
retina. PLoS One, 2011. 6(7): p. e21858. 
76. Gundogan, F.C., G. Sobaci, and M.Z. Bayraktar, Intra-sessional and inter-sessional variability 
of multifocal electroretinogram. Doc Ophthalmol, 2008. 117(3): p. 175-83. 
77. Harrison, W.W., et al., Multifocal electroretinograms predict onset of diabetic retinopathy in 
adult patients with diabetes. Invest Ophthalmol Vis Sci, 2011. 52(2): p. 772-7. 
78. Feigl, B., et al., Local neuroretinal function during acute hypoxia in healthy older people. 
Invest Ophthalmol, 2008. 49: p. 807-813. 
79. Grunwald, J.E., et al., Reduced foveolar choroidal blood flow in eyes with increasing AMD 
severity. Invest Ophthalmol Vis Sci, 2005. 46: p. 1033-1038. 
80. Moschos, M.M., et al., Ranibizumab in the treatment of choroidal neovascularisation due to 
age-related macular degeneration: an optical coherence tomography and multifocal 
electroretinography study. Clin Exp Optom, 2011. 94(3): p. 268-75. 
81. Moschos, M.M., et al., Assessment of macular function by multifocal electroretinography in 
age-related macular degeneration before and after photodynamic therapy. J Fr Ophthalmol, 
2004. 27: p. 1001-1006. 
 
  
 
 
 
 
 
 
 
 
 
 
Feigl B, Morris CP, Brown B, Zele AJ. Archives of Ophthalmology 2012;130(11):1402-1409. 
 
18 
 
 
Legends: 
 
Figure 1: Slow-flash multifocal electroretinogram (mfERG) arrays: hexagonal mfERG 
stimulus array of 5 concentric rings (A) and mfERG trace arrays showing the results of a 
representative sample of healthy participants with a high-risk genotype (B), or a low-risk 
genotype (C) and patients with early AMD (D) who demonstrated supernormal, normal and 
centrally delayed responses, respectively. 
 
 
Figure 2: Mean response densities for rings 1-5 of the three groups  of  individuals. The 
densities demonstrate significantly larger N1P1-RD for the healthy participants with high-risk 
genotypes compared to the healthy participants with low-risk genotype and the patietns with 
early age-related macular degeneration (AMD) (A). No significant difference was found in 
P1-implicit times for rings 1 to 5 among the three groups, but those were on average delayed 
for ring 1 in the early AMD group (lower panel) (B). Error bars indicate SD,*P≤.05 
 
 
Figure 3. Multifocal electroretinogram N1P1-RD are shown for an individual person of each 
of the three groups. The model suggests that in stage 1 (subclinical), persons with high-risk 
genotypes show supernormal responses in rings 1 to 3. As the disease becomes manifest 
(stage 2), responses decrease to “normal (low-risk)” values which are more pronounced in the 
para- and pericentral area (rings 2 and 3) where there are greatest changes in retinal 
topography (photoreceptor/bipolar cell loss) in AMD. In stage 3 of early AMD, neuroretinal 
responses have decreased further and below normal values which is reflected in progressive 
fundus changes (drusen size ≥ 125 μm). 
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Table 1. The demographic characteristics of healthy participants with high and low-risk 
genotypes and multifocal ERG response densities (in nV/deg2) and implicit times (in ms) 
 
Abbreviations: gen: gender, m: male, f: female, RD: response density, IT: implicit time, R1-R5: ring 1-ring 5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
age gen CFH/ARMS2 
genotype 
Risk 
 
RDR1 RDR2 RDR3 RDR4 RDR5 ITR1 ITR2 ITR3 ITR4 ITR5 
57 f CC/GT High risk 21.2 14.5 9.7 6.4 5.1 33.3 33.3 32.5 32.5 32.4 
48 m CC/GT High risk 20.1 13.6 9.5 6.9 5.1 35.8 34.2 34.2 34.2 32.5 
62 f CC/GT High risk 15.4 11.3 8.8 6.2 4.7 34.2 34.2 32.5 32.5 31.7 
57 m CC/GG High risk 18.6 11.5 8.3 5.8 4.6 33.3 33.3 33.3 33.3 32.5 
51 m CC/GG High risk 15.8 10.2 8.4 6.2 4.8 35.8 34.2 34.2 33.3 33.3 
53 f CC/GG High risk 18.4 11.2 9.2 6.7 4.9 35.0 33.3 32.5 32.5 31.7 
53 m CG/GT High risk 16.9 11.2 9.8 7.5 6.3 34.2 33.3 32.5 32.5 32.5 
52 f CG/GT High risk 16.6 10.6 8.7 6.4 4.8 35.0 33.3 33.3 33.3 33.3 
52 f CG/GT High risk 18.7 11.4 8.4 5.9 4.6 35.0 33.3 32.5 31.7 30.8 
57 m CG/GT High risk 19.5 12.3 8.2 6.9 6.3 36.7 35 33.3 33.3 33.3 
55 f CG/GT High risk 16.5 10.9 7.6 6.3 5.5 36.7 33.3 33.3 32.5 32.5 
56 m CG/GG Low risk 13.9 9 6 4.3 3.7 34.2 34.2 34.2 34.2 34.2 
63 f CG/GG Low risk 12.7 9.1 7.5 5.6 4.4 36.7 34.2 34.2 34.2 34.2 
61 f CG/GG Low  risk 15.9 10.5 8.6 6.4 5 33.3 32.5 3.5 32.5 32.5 
52 m CG/GG Low  risk 11.5 8.9 6.7 5.2 4.3 33.3 33.3 33.3 32.5 32.5 
60 m CG/GG Low  risk 11.5 8.3 7 4.8 2.8 35.8 35 34.2 34.2 33.3 
63 f CG/GG Low  risk 16.2 10.4 8.9 7.6 6.1 34.2 33.3 32.5 31.7 30.8 
53 m CG/GG Low  risk 14.7 8.7 6.4 5.7 4.8 35.8 35 34.2 32.5 32.5 
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Table 2. The characteristics of early AMD patients and multifocal ERG response density (in 
nV/deg2) and implicit time (in ms) results 
 
age gender RDR1 RDR2 RDR3 RDR4 RDR5 ITR1 ITR2 ITR3 ITR4 ITR5 
73 m 22.8 13.7 10 7.5 5.7 36.6 34.2 32.5 31.7 30.8 
74 f 18.1 10.1 6.5 5.1 4.6 35.8 35 34.2 1.7 31.7 
75 m 15.2 9.2 7.5 6.3 6.2 36.6 33.3 32.5 31.7 31.7 
73 m 13.9 8.5 8.1 7 6.6 37.5 32.5 32.5 31.7 31.7 
70 f 16 8.8 7.2 6.6 5.8 35 35 33.3 32.5 32.5 
69 m 13.7 7.9 7.1 6.5 5 36.6 32.5 31.7 31.7 30.8 
75 f 9.5 5.8 5.3 4.7 4.3 36.6 33.3 31.7 30.8 30 
75 f 6.9 6.4 5.9 4.9 3.9 34.2 34.2 34.2 34.2 33.3 
77 f 15.9 9.9 7.9 6.7 5.5 37.5 35 34.2 33.3 32.5 
69 f 21.7 10.6 7.7 6.8 5.4 36.6 33.3 30.8 30.8 30 
 
Abbreviations: m: male, f: female, RD: response density, IT: implicit time, R1-R5: ring 1-ring 5 
 
Table 3. The MPOD results and genotypes for the healthy participants 
 
Age MPOD genotype 
57 0.49 CC/GT (high risk) 
48 0.71 CC/GT (high risk) 
62 0.43 CC/GT (high risk) 
57 0.36 CC/GG (high risk) 
51 0.72 CC/GG (high risk) 
53 0.97 CC/GG (high risk) 
53 0.46 CG/GT (high risk) 
52 0.55 CG/GT (high risk) 
52 0.3 CG/GT (high risk) 
53 0.58 CG/GT (high risk) 
56 0.3 CG/GT (high risk) 
57 0.03 CG/GT (high risk) 
54 0.53 CG/GT (high risk) 
56 0.39 CG/GG (low risk) 
63 0.33 CG/GG (low risk) 
61 0.48 CG/GG (low risk) 
52 0.89 CG/GG (low risk) 
67 0.78 CG/GG (low risk) 
60 0.47 CG/GG (low risk) 
53 0.57 CG/GG (low risk) 
 
 
